Literature DB >> 23900458

MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells.

Hiroaki Nagano1, Yoshito Tomimaru, Hidetoshi Eguchi, Naoki Hama, Hiroshi Wada, Koichi Kawamoto, Shogo Kobayashi, Masaki Mori, Yuichiro Doki.   

Abstract

Although we studied previously the mechanisms of resistance of pancreatic cancer cells to gemcitabine (GEM), prediction of the response to GEM remains unsatisfactory. The aim of this study was to investigate the relationship between miR-29a expression and the response to GEM in pancreatic cancer cells. Changes in the growth-inhibitory effect of pancreatic cancer cells (MIAPaCa-2, PSN-1, BxPC-3 and Panc-1) to GEM were examined after overexpression or suppression of miR-29a. We also examined the effect of miR-29a on the Wnt/β-catenin signaling pathway and investigated whether the altered growth-inhibitory effect by miR-29a suppression was weakened after the addition of Wnt3a, a Wnt/β-catenin signaling activator. MIAPaCa-2 and PSN-1 cells transfected with anti-miR-29a showed significantly lower resistance to GEM. In the anti-miR-29a-transfected cells, GEM induced significantly larger numbers of apoptotic cells and S phase accumulation compared to control cells, demonstrated by Annexin V assay and flow cytometric analysis of the cell cycle, respectively. The transfected cells showed overexpression of putative target molecules including Dkk1, Kremen2 and sFRP2 and lower activation of the Wnt/β-catenin signaling pathway. The addition of Wnt3a weakened the augmented growth-inhibitory effect of anti-miR-29a transfection. Our findings suggest that miR-29a expression correlates significantly with the growth-inhibitory effect of GEM and that activation of the Wnt/β-catenin signaling pathway mediated the miR-29a-induced resistance to GEM in pancreatic cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23900458     DOI: 10.3892/ijo.2013.2037

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  32 in total

1.  Serum microRNA profiles as prognostic or predictive markers in the multimodality treatment of patients with gastric cancer.

Authors:  Leila Sisic; Daniel Vallböhmer; Nikolas H Stoecklein; Susanne Blank; Thomas Schmidt; Christiane Driemel; Birte Möhlendick; Wolfram T Knoefel; Margarete Odenthal; Katja Ott
Journal:  Oncol Lett       Date:  2015-06-09       Impact factor: 2.967

2.  Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.

Authors:  Yehua Shen; Yan Pan; Litao Xu; Lianyu Chen; Luming Liu; Hao Chen; Zhen Chen; Zhiqiang Meng
Journal:  Tumour Biol       Date:  2015-02-27

3.  Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.

Authors:  Chong-Chong Gao; Xiao-Lan Xu; Fei Li; Ben-Gang Gong; Shuang Liu; Ye-Qing Cui; Hai-Chen Sun; Ping-Yong Xu; Ya-Min Zheng; Hua Jiang
Journal:  Tumour Biol       Date:  2015-12-18

4.  Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.

Authors:  Penn Muluhngwi; Abirami Krishna; Stephany L Vittitow; Joshua T Napier; Kirsten M Richardson; Mackenzie Ellis; Justin L Mott; Carolyn M Klinge
Journal:  Cancer Lett       Date:  2016-12-13       Impact factor: 8.679

Review 5.  miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma.

Authors:  Anteneh A Tesfaye; Asfar S Azmi; Philip A Philip
Journal:  Am J Pathol       Date:  2019-01       Impact factor: 4.307

Review 6.  Developments in miRNA gene signaling pathways in pancreatic cancer.

Authors:  Christina Vorvis; Marina Koutsioumpa; Dimitrios Iliopoulos
Journal:  Future Oncol       Date:  2016-03-17       Impact factor: 3.404

7.  MicroRNA 217 inhibits cell proliferation and enhances chemosensitivity to doxorubicin in acute myeloid leukemia by targeting KRAS.

Authors:  Yi Xiao; Taoran Deng; Changliang Su; Zhen Shang
Journal:  Oncol Lett       Date:  2017-04-24       Impact factor: 2.967

8.  miR-33a suppresses the nuclear translocation of β-catenin to enhance gemcitabine sensitivity in human pancreatic cancer cells.

Authors:  Chen Liang; Zhen Wang; Ying-Yi Li; Bao-Hua Yu; Fei Zhang; Hong-Yu Li
Journal:  Tumour Biol       Date:  2015-06-26

Review 9.  MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer.

Authors:  Marion Gayral; Sébastien Jo; Naima Hanoun; Alix Vignolle-Vidoni; Hubert Lulka; Yannick Delpu; Aline Meulle; Marlène Dufresne; Marine Humeau; Maël Chalret du Rieu; Barbara Bournet; Janick Sèlves; Rosine Guimbaud; Nicolas Carrère; Louis Buscail; Jérôme Torrisani; Pierre Cordelier
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 10.  Advances in pancreatic cancer research: moving towards early detection.

Authors:  Xiang-Yi He; Yao-Zong Yuan
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.